{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:37:46Z","timestamp":1788910666679,"version":"build-2803163510"},"reference-count":108,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The delivery of drugs to the brain is quite challenging in the treatment of the central nervous\nsystem (CNS) diseases due to the blood-brain barrier and the blood-cerebrospinal fluid barrier. However,\nsignificant developments in nanomaterials employed by nanoparticle drug-delivery systems have\nsubstantial potential to cross or bypass these barriers leading to enhanced therapeutic efficacies. Advances\nin nanoplatform, nanosystems based on lipids, polymers and inorganic materials have been extensively\nstudied and applied in treating Alzheimer's and Parkinson's diseases. In this review, various\ntypes of brain drug delivery nanocarriers are classified, summarized, and their potential as drug delivery\nsystems in Alzheimer's and Parkinson's diseases is discussed. Finally, challenges facing the clinical\ntranslation of nanoparticles from bench to bedside are highlighted.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201820666230707113405","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T06:06:40Z","timestamp":1688969200000},"page":"917-931","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's\nDiseases"],"prefix":"10.2174","volume":"21","author":[{"given":"Phuong-Trang","family":"Nguyen-Thi","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, HUTECH University, Ho Chi Minh City 700000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh-Tam","family":"Ho","sequence":"additional","affiliation":[{"name":"Institute for Global Health Innovations,\nDuy Tan University, Da Nang 550000, Vietnam"},{"name":"Faculty of Pharmacy, Duy Tan University, Da Nang 550000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy Trang","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Faculty of Chemical Engineering, Industrial University of Ho Chi Minh City, Ho Chi Minh City 71420, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giau Van","family":"Vo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, School of Medicine, Vietnam National University, Ho Chi Minh City\n[VNU-HCM], Ho Chi Minh City 700000, Vietnam"},{"name":"Research Center for Genetics and Reproductive Health [CGRH],\nSchool of Medicine, Vietnam National University, Ho Chi Minh City [VNU-HCM], Ho Chi Minh City 70000, Vietnam"},{"name":"Vietnam National University, Ho Chi Minh City [VNU-HCM], Ho Chi Minh City 700000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"Feigin V.L.","year":"2019","unstructured":"Feigin V.L.; Nichols E.; Alam T.; Bannick M.S.; Beghi E.; Blake N.; Culpepper W.J.; Dorsey E.R.; Elbaz A.; Ellenbogen R.G.; Fisher J.L.; Fitzmaurice C.; Giussani G.; Glennie L.; James S.L.; Johnson C.O.; Kassebaum N.J.; Logroscino G.; Marin B.; Mountjoy-Venning W.C.; Nguyen M.; Ofori-Asenso R.; Patel A.P.; Piccininni M.; Roth G.A.; Steiner T.J.; Stovner L.J.; Szoeke C.E.I.; Theadom A.; Vollset S.E.; Wallin M.T.; Wright C.; Zunt J.R.; Abbasi N.; Abd-Allah F.; Abdelalim A.; Abdollahpour I.; Aboyans V.; Abraha H.N.; Acharya D.; Adamu A.A.; Adebayo O.M.; Adeoye A.M.; Adsuar J.C.; Afarideh M.; Agrawal S.; Ahmadi A.; Ahmed M.B.; Aichour A.N.; Aichour I.; Aichour M.T.E.; Akinyemi R.O.; Akseer N.; Al-Eyadhy A.; Al-Shahi Salman R.; Alahdab F.; Alene K.A.; Aljunid S.M.; Altirkawi K.; Alvis-Guzman N.; Anber N.H.; Antonio C.A.T.; Arabloo J.; Aremu O.; \u00c4rnl\u00f6v J.; Asayesh H.; Asghar R.J.; Atalay H.T.; Awasthi A.; Ayala Quintanilla B.P.; Ayuk T.B.; Badawi A.; Banach M.; Banoub J.A.M.; Barboza M.A.; Barker-Collo S.L.; B\u00e4rnighausen T.W.; Baune B.T.; Bedi N.; Behzadifar M.; Behzadifar M.; B\u00e9jot Y.; Bekele B.B.; Belachew A.B.; Bennett D.A.; Bensenor I.M.; Berhane A.; Beuran M.; Bhattacharyya K.; Bhutta Z.A.; Biadgo B.; Bijani A.; Bililign N.; Bin Sayeed M.S.; Blazes C.K.; Brayne C.; Butt Z.A.; Campos-Nonato I.R.; Cantu-Brito C.; Car M.; C\u00e1rdenas R.; Carrero J.J.; Carvalho F.; Casta\u00f1eda-Orjuela C.A.; Castro F.; Catal\u00e1-L\u00f3pez F.; Cerin E.; Chaiah Y.; Chang J-C.; Chatziralli I.; Chiang P.P-C.; Christensen H.; Christopher D.J.; Cooper C.; Cortesi P.A.; Costa V.M.; Criqui M.H.; Crowe C.S.; Damasceno A.A.M.; Daryani A.; De la Cruz-G\u00f3ngora V.; De la Hoz F.P.; De Leo D.; Demoz G.T.; Deribe K.; Dharmaratne S.D.; Diaz D.; Dinberu M.T.; Djalalinia S.; Doku D.T.; Dubey M.; Dubljanin E.; Duken E.E.; Edvardsson D.; El-Khatib Z.; Endres M.; Endries A.Y.; Eskandarieh S.; Esteghamati A.; Esteghamati S.; Farhadi F.; Faro A.; Farzadfar F.; Farzaei M.H.; Fatima B.; Fereshtehnejad S-M.; Fernandes E.; Feyissa G.T.; Filip I.; Fischer F.; Fukumoto T.; Ganji M.; Gankpe F.G.; Garcia-Gordillo M.A.; Gebre A.K.; Gebremichael T.G.; Gelaw B.K.; Geleijnse J.M.; Geremew D.; Gezae K.E.; Ghasemi-Kasman M.; Gidey M.Y.; Gill P.S.; Gill T.K.; Girma E.T.; Gnedovskaya E.V.; Goulart A.C.; Grada A.; Grosso G.; Guo Y.; Gupta R.; Gupta R.; Haagsma J.A.; Hagos T.B.; Haj-Mirzaian A.; Haj-Mirzaian A.; Hamadeh R.R.; Hamidi S.; Hankey G.J.; Hao Y.; Haro J.M.; Hassankhani H.; Hassen H.Y.; Havmoeller R.; Hay S.I.; Hegazy M.I.; Heidari B.; Henok A.; Heydarpour F.; Hoang C.L.; Hole M.K.; Homaie Rad E.; Hosseini S.M.; Hu G.; Igumbor E.U.; Ilesanmi O.S.; Irvani S.S.N.; Islam S.M.S.; Jakovljevic M.; Javanbakht M.; Jha R.P.; Jobanputra Y.B.; Jonas J.B.; Jozwiak J.J.; J\u00fcrisson M.; Kahsay A.; Kalani R.; Kalkonde Y.; Kamil T.A.; Kanchan T.; Karami M.; Karch A.; Karimi N.; Kasaeian A.; Kassa T.D.; Kassa Z.Y.; Kaul A.; Kefale A.T.; Keiyoro P.N.; Khader Y.S.; Khafaie M.A.; Khalil I.A.; Khan E.A.; Khang Y-H.; Khazaie H.; Kiadaliri A.A.; Kiirithio D.N.; Kim A.S.; Kim D.; Kim Y-E.; Kim Y.J.; Kisa A.; Kokubo Y.; Koyanagi A.; Krishnamurthi R.V.; Kuate Defo B.; Kucuk Bicer B.; Kumar M.; Lacey B.; Lafranconi A.; Lansingh V.C.; Latifi A.; Leshargie C.T.; Li S.; Liao Y.; Linn S.; Lo W.D.; Lopez J.C.F.; Lorkowski S.; Lotufo P.A.; Lucas R.M.; Lunevicius R.; Mackay M.T.; Mahotra N.B.; Majdan M.; Majdzadeh R.; Majeed A.; Malekzadeh R.; Malta D.C.; Manafi N.; Mansournia M.A.; Mantovani L.G.; M\u00e4rz W.; Mashamba-Thompson T.P.; Massenburg B.B.; Mate K.K.V.; McAlinden C.; McGrath J.J.; Mehta V.; Meier T.; Meles H.G.; Melese A.; Memiah P.T.N.; Memish Z.A.; Mendoza W.; Mengistu D.T.; Mengistu G.; Meretoja A.; Meretoja T.J.; Mestrovic T.; Miazgowski B.; Miazgowski T.; Miller T.R.; Mini G.K.; Mirrakhimov E.M.; Moazen B.; Mohajer B.; Mohammad Gholi Mezerji N.; Mohammadi M.; Mohammadi-Khanaposhtani M.; Mohammadibakhsh R.; Mohammadnia-Afrouzi M.; Mohammed S.; Mohebi F.; Mokdad A.H.; Monasta L.; Mondello S.; Moodley Y.; Moosazadeh M.; Moradi G.; Moradi-Lakeh M.; Moradinazar M.; Moraga P.; Moreno Vel\u00e1squez I.; Morrison S.D.; Mousavi S.M.; Muhammed O.S.; Muruet W.; Musa K.I.; Mustafa G.; Naderi M.; Nagel G.; Naheed A.; Naik G.; Najafi F.; Nangia V.; Negoi I.; Negoi R.I.; Newton C.R.J.; Ngunjiri J.W.; Nguyen C.T.; Nguyen L.H.; Ningrum D.N.A.; Nirayo Y.L.; Nixon M.R.; Norrving B.; Noubiap J.J.; Nourollahpour Shiadeh M.; Nyasulu P.S.; Ogah O.S.; Oh I-H.; Olagunju A.T.; Olagunju T.O.; Olivares P.R.; Onwujekwe O.E.; Oren E.; Owolabi M.O.; Pa M.; Pakpour A.H.; Pan W-H.; Panda-Jonas S.; Pandian J.D.; Patel S.K.; Pereira D.M.; Petzold M.; Pillay J.D.; Piradov M.A.; Polanczyk G.V.; Polinder S.; Postma M.J.; Poulton R.; Poustchi H.; Prakash S.; Prakash V.; Qorbani M.; Radfar A.; Rafay A.; Rafiei A.; Rahim F.; Rahimi-Movaghar V.; Rahman M.; Rahman M.H.U.; Rahman M.A.; Rajati F.; Ram U.; Ranta A.; Rawaf D.L.; Rawaf S.; Reinig N.; Reis C.; Renzaho A.M.N.; Resnikoff S.; Rezaeian S.; Rezai M.S.; Rios Gonz\u00e1lez C.M.; Roberts N.L.S.; Roever L.; Ronfani L.; Roro E.M.; Roshandel G.; Rostami A.; Sabbagh P.; Sacco R.L.; Sachdev P.S.; Saddik B.; Safari H.; Safari-Faramani R.; Safi S.; Safiri S.; Sagar R.; Sahathevan R.; Sahebkar A.; Sahraian M.A.; Salamati P.; Salehi Zahabi S.; Salimi Y.; Samy A.M.; Sanabria J.; Santos I.S.; Santric Milicevic M.M.; Sarrafzadegan N.; Sartorius B.; Sarvi S.; Sathian B.; Satpathy M.; Sawant A.R.; Sawhney M.; Schneider I.J.C.; Sch\u00f6ttker B.; Schwebel D.C.; Seedat S.; Sepanlou S.G.; Shabaninejad H.; Shafieesabet A.; Shaikh M.A.; Shakir R.A.; Shams-Beyranvand M.; Shamsizadeh M.; Sharif M.; Sharif-Alhoseini M.; She J.; Sheikh A.; Sheth K.N.; Shigematsu M.; Shiri R.; Shirkoohi R.; Shiue I.; Siabani S.; Siddiqi T.J.; Sigfusdottir I.D.; Sigurvinsdottir R.; Silberberg D.H.; Silva J.P.; Silveira D.G.A.; Singh J.A.; Sinha D.N.; Skiadaresi E.; Smith M.; Sobaih B.H.; Sobhani S.; Soofi M.; Soyiri I.N.; Sposato L.A.; Stein D.J.; Stein M.B.; Stokes M.A.; Sufiyan M.B.; Sykes B.L.; Sylaja P.N.; Tabar\u00e9s-Seisdedos R.; Te Ao B.J.; Tehrani-Banihashemi A.; Temsah M-H.; Temsah O.; Thakur J.S.; Thrift A.G.; Topor-Madry R.; Tortajada-Girb\u00e9s M.; Tovani-Palone M.R.; Tran B.X.; Tran K.B.; Truelsen T.C.; Tsadik A.G.; Tudor Car L.; Ukwaja K.N.; Ullah I.; Usman M.S.; Uthman O.A.; Valdez P.R.; Vasankari T.J.; Vasanthan R.; Veisani Y.; Venketasubramanian N.; Violante F.S.; Vlassov V.; Vosoughi K.; Vu G.T.; Vujcic I.S.; Wagnew F.S.; Waheed Y.; Wang Y-P.; Weiderpass E.; Weiss J.; Whiteford H.A.; Wijeratne T.; Winkler A.S.; Wiysonge C.S.; Wolfe C.D.A.; Xu G.; Yadollahpour A.; Yamada T.; Yano Y.; Yaseri M.; Yatsuya H.; Yimer E.M.; Yip P.; Yisma E.; Yonemoto N.; Yousefifard M.; Yu C.; Zaidi Z.; Zaman S.B.; Zamani M.; Zandian H.; Zare Z.; Zhang Y.; Zodpey S.; Naghavi M.; Murray C.J.L.; Vos T.; Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol  2019,18(5),459-480","journal-title":"Lancet Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1900159","DOI":"10.1002\/adtp.201900159","volume":"3","author":"Feng L.","year":"2020","unstructured":"Feng L.; Wang H.; Xue X.; Recent Progress of Nanomedicine in the Treatment of Central Nervous System Diseases. Adv Ther (Weinh)  2020,3(5),1900159","journal-title":"Adv Ther (Weinh)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00702-006-0606-3","volume":"114","author":"Korczyn A.D.","year":"2007","unstructured":"Korczyn A.D.; Reichmann H.; Boroojerdi B.; H\u00e4ck H.J.; Rotigotine transdermal system for perioperative administration. J Neural Transm (Vienna)  2007,114(2),219-221","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1093\/brain\/awp234","volume":"132","author":"Selikhova M.","year":"2009","unstructured":"Selikhova M.; Williams D.R.; Kempster P.A.; Holton J.L.; Revesz T.; Lees A.J.; A clinico-pathological study of subtypes in Parkinson\u2019s disease. Brain  2009,132(11),2947-2957","journal-title":"Brain"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/NRL.0b013e31815b0de2","volume":"14","author":"Bonelli R.M.","year":"2008","unstructured":"Bonelli R.M.; Cummings J.L.; Frontal-Subcortical Dementias. Neurologist  2008,14(2),100-107","journal-title":"Neurologist"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"139111623","DOI":"10.1016\/j.biopha.2021.111623","author":"Nguyen T.T.","year":"2021","unstructured":"Nguyen T.T.; Nguyen T.T.D.; Nguyen T.K.O.; Vo T.K.; Vo V.G.; Advances in developing therapeutic strategies for Alzheimer\u2019s disease. Biomed Pharmacother  2021,139111623","journal-title":"Biomed Pharmacother"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/NDT.S2006","volume":"4","author":"Jankovic J.","year":"2008","unstructured":"Jankovic J.; Aguilar L.G.; Current approaches to the treatment of Parkinson\u2019s disease. Neuropsychiatr Dis Treat  2008,4(4),743-757","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3109\/09687688.2014.937468","volume":"31","author":"Tajes M.","year":"2014","unstructured":"Tajes M.; Ramos-Fern\u00e1ndez E.; Weng-Jiang X.; Bosch-Morat\u00f3 M.; Guivernau B.; Eraso-Pichot A.; Salvador B.; Fern\u00e0ndez-Busquets X.; Roquer J.; Mu\u00f1oz F.J.; The blood-brain barrier: Structure, function and therapeutic approaches to cross it. Mol Membr Biol  2014,31(5),152-167","journal-title":"Mol Membr Biol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1021\/acs.nanolett.9b04683","volume":"20","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Zou Y.; Feng C.; Lee A.; Yin J.; Chung R.; Park J.B.; Rizos H.; Tao W.; Zheng M.; Farokhzad O.C.; Shi B.; Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy. Nano Lett  2020,20(3),1637-1646","journal-title":"Nano Lett"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1800053","DOI":"10.1002\/adtp.201800053","volume":"1","author":"Lang T.","year":"2018","unstructured":"Lang T.; Yin Q.; Li Y.; Progress of Cell-Derived Biomimetic Drug Delivery Systems for Cancer Therapy. Adv Ther (Weinh)  2018,1(7),1800053","journal-title":"Adv Ther (Weinh)"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-08-102548-2.00004-4","author":"Garc\u00eda M.C.","year":"2020","unstructured":"Garc\u00eda M.C.;  Engineering Drug Delivery Systems  2020,71-110","journal-title":"Engineering Drug Delivery Systems"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jsps.2021.07.015","volume":"29","author":"Elmowafy M.","year":"2021","unstructured":"Elmowafy M.; Al-Sanea M.M.; Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm J  2021,29(9),999-1012","journal-title":"Saudi Pharm J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3746\/pnf.2019.24.3.225","volume":"24","author":"Kumar M.","year":"2019","unstructured":"Kumar M.; Bishnoi R.S.; Shukla A.K.; Jain C.P.; Techniques for Formulation of Nanoemulsion Drug Delivery System: A Review. Prev Nutr Food Sci  2019,24(3),225-234","journal-title":"Prev Nutr Food Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2008171","DOI":"10.1002\/adfm.202008171","volume":"31","author":"Liu Q.","year":"2021","unstructured":"Liu Q.; Kim Y.J.; Im G-B.; Zhu J.; Wu Y.; Liu Y.; Bhang S.H.; Inorganic Nanoparticles Applied as Functional Therapeutics. Adv Funct Mater  2021,31(12),2008171","journal-title":"Adv Funct Mater"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1021\/acscentsci.1c01272","volume":"7","author":"Heuer-Jungemann A.","year":"2021","unstructured":"Heuer-Jungemann A.; Linko V.; Engineering Inorganic Materials with DNA Nanostructures. ACS Cent Sci  2021,7(12),1969-1979","journal-title":"ACS Cent Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"7587012","DOI":"10.3389\/fmolb.2020.587012","author":"Sanit\u00e0 G.","year":"2020","unstructured":"Sanit\u00e0 G.; Carrese B.; Lamberti A.; Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization. Front Mol Biosci  2020,7587012","journal-title":"Front Mol Biosci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.addr.2016.02.008","volume":"103","author":"Nair M.","year":"2016","unstructured":"Nair M.; Jayant R.D.; Kaushik A.; Sagar V.; Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev  2016,103,202-217","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"Pardridge W.M.","year":"2012","unstructured":"Pardridge W.M.; Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab  2012,32(11),1959-1972","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e1153568","DOI":"10.1080\/21688370.2016.1153568","volume":"4","author":"Grabrucker A.M.","year":"2016","unstructured":"Grabrucker A.M.; Ruozi B.; Belletti D.; Pederzoli F.; Forni F.; Vandelli M.A.; Tosi G.; Nanoparticle transport across the blood brain barrier. Tissue Barriers  2016,4(1),e1153568","journal-title":"Tissue Barriers"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s11095-007-9379-0","volume":"24","author":"Jones A.R.","year":"2007","unstructured":"Jones A.R.; Shusta E.V.; Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res  2007,24(9),1759-1771","journal-title":"Pharm Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"Saraiva C.","year":"2016","unstructured":"Saraiva C.; Pra\u00e7a C.; Ferreira R.; Santos T.; Ferreira L.; Bernardino L.; Nanoparticle-mediated brain drug delivery: Overcoming blood\u2013brain barrier to treat neurodegenerative diseases. J Control Release  2016,235,34-47","journal-title":"J Control Release"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3389\/fphar.2019.00724","volume":"10","author":"Ingusci S.","year":"2019","unstructured":"Ingusci S.; Verlengia G.; Soukupova M.; Zucchini S.; Simonato M.; Gene Therapy Tools for Brain Diseases. Front Pharmacol  2019,10,724","journal-title":"Front Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fncel.2012.00044","volume":"6","author":"Ribeiro M.M.B.","year":"2012","unstructured":"Ribeiro M.M.B.; Domingues M.M.; Freire J.M.; Santos N.C.; Castanho M.A.R.B.; Translocating the blood-brain barrier using electrostatics. Front Cell Neurosci  2012,6,44","journal-title":"Front Cell Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2003937","DOI":"10.1002\/advs.202003937","volume":"8","author":"Zhang W.","year":"2021","unstructured":"Zhang W.; Mehta A.; Tong Z.; Esser L.; Voelcker N.H.; Development of Polymeric Nanoparticles for Blood\u2013Brain Barrier Transfer\u2014Strategies and Challenges. Adv Sci (Weinh)  2021,8(10),2003937","journal-title":"Adv Sci (Weinh)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jconrel.2019.01.005","volume":"295","author":"Johnsen KB","year":"2019","unstructured":"Johnsen KB; Bak M; Melander F; Thomsen MS; Burkhart A; Kempen PJ; Modulating the antibody density changes the uptake and transport at the blood-brain barrier of both transferrin receptortargeted gold nanoparticles and liposomal cargo. J contr rel  2019,295,237-249","journal-title":"J contr rel"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.3390\/ijms23084153","volume":"23","author":"Hersh A.M.","year":"2022","unstructured":"Hersh A.M.; Alomari S.; Tyler B.M.; Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. Int J Mol Sci  2022,23(8),4153","journal-title":"Int J Mol Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000101884","volume":"4","author":"Jain K.K.","year":"2007","unstructured":"Jain K.K.; Nanobiotechnology-based drug delivery to the central nervous system. Neurodegener Dis  2007,4(4),287-291","journal-title":"Neurodegener Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1056\/NEJMra040223","volume":"351","author":"Cummings J.L.","year":"2004","unstructured":"Cummings J.L.; Alzheimer\u2019s Disease. N Engl J Med  2004,351(1),56-67","journal-title":"N Engl J Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1002\/anie.200802808","volume":"48","author":"Jakob-Roetne R.","year":"2009","unstructured":"Jakob-Roetne R.; Jacobsen H.; Alzheimer\u2019s disease: from pathology to therapeutic approaches. Angew Chem Int Ed  2009,48(17),3030-3059","journal-title":"Angew Chem Int Ed"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s11064-020-03031-0","volume":"45","author":"Nguyen T.T.","year":"2020","unstructured":"Nguyen T.T.; Ta Q.T.H.; Nguyen T.T.D.; Le T.T.; Vo V.G.; Role of Insulin Resistance in the Alzheimer\u2019s Disease Progression. Neurochem Res  2020,45(7),1481-1491","journal-title":"Neurochem Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/ijms21093165","volume":"21","author":"Nguyen T.T.","year":"2020","unstructured":"Nguyen T.T.; Ta Q.T.H.; Nguyen T.K.O.; Nguyen T.T.D.; Van Giau V.; Type 3 Diabetes and Its Role Implications in Alzheimer\u2019s Disease. Int J Mol Sci  2020,21(9),3165","journal-title":"Int J Mol Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jns.2017.03.031","volume":"376","author":"Bagyinszky E.","year":"2017","unstructured":"Bagyinszky E.; Giau V.V.; Shim K.; Suk K.; An S.S.A.; Kim S.; Role of inflammatory molecules in the Alzheimer\u2019s disease progression and diagnosis. J Neurol Sci  2017,376,242-254","journal-title":"J Neurol Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.mcna.2018.10.009","volume":"103","author":"Atri A.","year":"2019","unstructured":"Atri A.; The Alzheimer\u2019s Disease Clinical Spectrum. Med Clin North Am  2019,103(2),263-293","journal-title":"Med Clin North Am"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","volume":"9","author":"Thies W.","year":"2013","unstructured":"Thies W.; Bleiler L.; Bleiler L.; 2013 Alzheimer\u2019s disease facts and figures. Alzheimers Dement  2013,9(2),208-245","journal-title":"Alzheimers Dement"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/msj.20157","volume":"77","author":"Perl D.P.","year":"2010","unstructured":"Perl D.P.; Neuropathology of Alzheimer\u2019s disease. Mt Sinai J Med  2010,77(1),32-42","journal-title":"Mt Sinai J Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2217\/imt.10.80","volume":"2","author":"Panza F.","year":"2010","unstructured":"Panza F.; Frisardi V.; Imbimbo B.P.; D\u2019Onofrio G.; Pietrarossa G.; Seripa D.; Pilotto A.; Solfrizzi V.; Bapineuzumab: anti-\u03b2-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. Immunotherapy  2010,2(6),767-782","journal-title":"Immunotherapy"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1517\/14712598.2013.789856","volume":"13","author":"Tayeb H.O.","year":"2013","unstructured":"Tayeb H.O.; Murray E.D.; Price B.H.; Tarazi F.I.; Bapineuzumab and solanezumab for Alzheimer\u2019s disease: is the \u2018amyloid cascade hypothesis\u2019 still alive? Expert Opin Biol Ther  2013,13(7),1075-1084","journal-title":"Expert Opin Biol Ther"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","volume":"69","author":"Ostrowitzki S.","year":"2012","unstructured":"Ostrowitzki S.; Deptula D.; Thurfjell L.; Barkhof F.; Bohrmann B.; Brooks D.J.; Klunk W.E.; Ashford E.; Yoo K.; Xu Z.X.; Loetscher H.; Santarelli L.; Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol  2012,69(2),198-207","journal-title":"Arch Neurol"},{"key":"ref=39","first-page":"197","volume":"9","author":"Budd Haeberlein S.","year":"2022","unstructured":"Budd Haeberlein S.; Aisen P.S.; Barkhof F.; Chalkias S.; Chen T.; Cohen S.; Dent G.; Hansson O.; Harrison K.; von Hehn C.; Iwatsubo T.; Mallinckrodt C.; Mummery C.J.; Muralidharan K.K.; Nestorov I.; Nisenbaum L.; Rajagovindan R.; Skordos L.; Tian Y.; van Dyck C.H.; Vellas B.; Wu S.; Zhu Y.; Sandrock A.; Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease. J Prev Alzheimers Dis  2022,9(2),197-210","journal-title":"J Prev Alzheimers Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"van Dyck C.H.","year":"2023","unstructured":"van Dyck C.H.; Swanson C.J.; Aisen P.; Bateman R.J.; Chen C.; Gee M.; Kanekiyo M.; Li D.; Reyderman L.; Cohen S.; Froelich L.; Katayama S.; Sabbagh M.; Vellas B.; Watson D.; Dhadda S.; Irizarry M.; Kramer L.D.; Iwatsubo T.; Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med  2023,388(1),9-21","journal-title":"N Engl J Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1021\/nn4058215","volume":"8","author":"Song Q.","year":"2014","unstructured":"Song Q.; Huang M.; Yao L.; Wang X.; Gu X.; Chen J.; Chen J.; Huang J.; Hu Q.; Kang T.; Rong Z.; Qi H.; Zheng G.; Chen H.; Gao X.; Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer\u2019s disease by accelerating the clearance of amyloid-beta. ACS Nano  2014,8(3),2345-2359","journal-title":"ACS Nano"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"166107082","DOI":"10.1016\/j.nlm.2019.107082","author":"Dara T.","year":"2019","unstructured":"Dara T.; Vatanara A.; Sharifzadeh M.; Khani S.; Vakilinezhad M.A.; Vakhshiteh F.; Nabi Meybodi M.; Sadegh Malvajerd S.; Hassani S.; Mosaddegh M.H.; Improvement of memory deficits in the rat model of Alzheimer\u2019s disease by erythropoietin-loaded solid lipid nanoparticles. Neurobiol Learn Mem  2019,166107082","journal-title":"Neurobiol Learn Mem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1021\/acschemneuro.9b00691","volume":"11","author":"Mohamadpour H.","year":"2020","unstructured":"Mohamadpour H.; Azadi A.; Rostamizadeh K.; Andalib S.; Saghatchi Zanjani M.R.; Hamidi M.; Preparation, Optimization, and Evaluation of Methoxy Poly(ethylene glycol)- co -Poly(\u03b5-caprolactone) Nanoparticles Loaded by Rivastigmine for Brain Delivery. ACS Chem Neurosci  2020,11(5),783-795","journal-title":"ACS Chem Neurosci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"12833","DOI":"10.1021\/acsomega.9b01411","volume":"4","author":"Sonawane S.K.","year":"2019","unstructured":"Sonawane S.K.; Ahmad A.; Chinnathambi S.; Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer\u2019s Disease. ACS Omega  2019,4(7),12833-12840","journal-title":"ACS Omega"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bioactmat.2020.08.017","volume":"6","author":"Han Y.","year":"2021","unstructured":"Han Y.; Gao C.; Wang H.; Sun J.; Liang M.; Feng Y.; Liu Q.; Fu S.; Cui L.; Gao C.; Li Y.; Yang Y.; Sun B.; Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer\u2019s disease mice. Bioact Mater  2021,6(2),529-542","journal-title":"Bioact Mater"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"13757","DOI":"10.1039\/D0NR04037A","volume":"12","author":"Burilova E.A.","year":"2020","unstructured":"Burilova E.A.; Pashirova T.N.; Zueva I.V.; Gibadullina E.M.; Lushchekina S.V.; Sapunova A.S.; Kayumova R.M.; Rogov A.M.; Evtjugin V.G.; Sudakov I.A.; Vyshtakalyuk A.B.; Voloshina A.D.; Bukharov S.V.; Burilov A.R.; Petrov K.A.; Zakharova L.Y.; Sinyashin O.G.; Bi-functional sterically hindered phenol lipid-based delivery systems as potential multi-target agents against Alzheimer\u2019s disease via an intranasal route. Nanoscale  2020,12(25),13757-13770","journal-title":"Nanoscale"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1021\/acschemneuro.9b00343","volume":"10","author":"Krishna K.V.","year":"2019","unstructured":"Krishna K.V.; Wadhwa G.; Alexander A.; Kanojia N.; Saha R.N.; Kukreti R.; Singhvi G.; Dubey S.K.; Design and Biological Evaluation of Lipoprotein-Based Donepezil Nanocarrier for Enhanced Brain Uptake through Oral Delivery. ACS Chem Neurosci  2019,10(9),4124-4135","journal-title":"ACS Chem Neurosci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijbiomac.2017.07.021","volume":"105","author":"AnjiReddy K.","year":"2017","unstructured":"AnjiReddy K.; Karpagam S.; Chitosan nanofilm and electrospun nanofiber for quick drug release in the treatment of Alzheimer\u2019s disease: In vitro and in vivo evaluation. Int J Biol Macromol  2017,105(Pt 1),131-142","journal-title":"Int J Biol Macromol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1166\/jbn.2014.1719","volume":"10","author":"Pagar K.P.","year":"2014","unstructured":"Pagar K.P.; Sardar S.M.; Vavia P.R.; Novel L-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer\u2019s disease. J Biomed Nanotechnol  2014,10(3),415-426","journal-title":"J Biomed Nanotechnol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/03639045.2012.758130","volume":"40","author":"Md S.","year":"2014","unstructured":"Md S.; Ali M.; Baboota S.; Sahni J.K.; Bhatnagar A.; Ali J.; Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev Ind Pharm  2014,40(2),278-287","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","volume":"47","author":"Fazil M.","year":"2012","unstructured":"Fazil M.; Md S.; Haque S.; Kumar M.; Baboota S.; Sahni J.; Ali J.; Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci  2012,47(1),6-15","journal-title":"Eur J Pharm Sci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1021\/cn900027u","volume":"1","author":"Cabaleiro-Lago C.","year":"2010","unstructured":"Cabaleiro-Lago C.; Quinlan-Pluck F.; Lynch I.; Dawson K.A.; Linse S.; Dual effect of amino modified polystyrene nanoparticles on amyloid \u03b2 protein fibrillation. ACS Chem Neurosci  2010,1(4),279-287","journal-title":"ACS Chem Neurosci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"6720","DOI":"10.1039\/C4NR00291A","volume":"6","author":"Luo J.","year":"2014","unstructured":"Luo J.; W\u00e4rml\u00e4nder S.K.T.S.; Yu C.H.; Muhammad K.; Gr\u00e4slund A.; Pieter Abrahams J.; The A\u03b2 peptide forms non-amyloid fibrils in the presence of carbon nanotubes. Nanoscale  2014,6(12),6720-6726","journal-title":"Nanoscale"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.bpj.2009.07.014","volume":"97","author":"Fu Z.","year":"2009","unstructured":"Fu Z.; Luo Y.; Derreumaux P.; Wei G.; Induced  \u03b2-Barrel Formation of the  Alzheimer\u2019s A\u03b225\u201335 Oligomers on Carbon Nanotube Surfaces: Implication for Amyloid Fibril Inhibition Biophys J  2009,97(6),1795-1803","journal-title":"Biophys J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"Poewe W.","year":"2017","unstructured":"Poewe W.; Seppi K.; Tanner C.M.; Halliday G.M.; Brundin P.; Volkmann J.; Schrag A.E.; Lang A.E.; Parkinson disease. Nat Rev Dis Primers  2017,3(1),17013","journal-title":"Nat Rev Dis Primers"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"Stefanis L.","year":"2012","unstructured":"Stefanis L.; \u03b1-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med  2012,2(2),a009399","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijpharm.2009.08.021","volume":"382","author":"Pillay S.","year":"2009","unstructured":"Pillay S.; Pillay V.; Choonara Y.E.; Naidoo D.; Khan R.A.; du Toit L.C.; Ndesendo V.M.K.; Modi G.; Danckwerts M.P.; Iyuke S.E.; Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Int J Pharm  2009,382(1-2),277-290","journal-title":"Int J Pharm"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/21691401.2018.1430583","volume":"46","author":"Yoosefian M.","year":"2018","unstructured":"Yoosefian M.; Rahmanifar E.; Etminan N.; Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis. Artif Cells Nanomed Biotechnol  2018,46,434-446","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"39557","DOI":"10.1021\/acsami.8b17224","volume":"10","author":"Fernandes C.","year":"2018","unstructured":"Fernandes C.; Martins C.; Fonseca A.; Nunes R.; Matos M.J.; Silva R.; Garrido J.; Sarmento B.; Remi\u00e3o F.; Otero-Espinar F.J.; Uriarte E.; Borges F.; PEGylated PLGA Nanoparticles As a Smart Carrier to Increase the Cellular Uptake of a Coumarin-Based Monoamine Oxidase B Inhibitor. ACS Appl Mater Interfaces  2018,10(46),39557-39569","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1021\/acschemneuro.6b00207","volume":"7","author":"Kundu P.","year":"2016","unstructured":"Kundu P.; Das M.; Tripathy K.; Sahoo S.K.; Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood\u2013Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson\u2019s Disease. ACS Chem Neurosci  2016,7(12),1658-1670","journal-title":"ACS Chem Neurosci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.7150\/thno.28295","volume":"8","author":"Li Y.","year":"2018","unstructured":"Li Y.; Chen Z.; Lu Z.; Yang Q.; Liu L.; Jiang Z.; Zhang L.; Zhang X.; Qing H.; \u201cCell-addictive\u201d dual-target traceable nanodrug for Parkinson\u2019s disease treatment via flotillins pathway. Theranostics  2018,8(19),5469-5481","journal-title":"Theranostics"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fbioe.2020.00112","volume":"8","author":"Zhao N.","year":"2020","unstructured":"Zhao N.; Yang X.; Calvelli H.R.; Cao Y.; Francis N.L.; Chmielowski R.A.; Joseph L.B.; Pang Z.P.; Uhrich K.E.; Baum J.; Moghe P.V.; Antioxidant Nanoparticles for Concerted Inhibition of \u03b1-Synuclein Fibrillization, and Attenuation of Microglial Intracellular Aggregation and Activation. Front Bioeng Biotechnol  2020,8,112","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/sj.gt.3302669","volume":"13","author":"Manfredsson F.P.","year":"2006","unstructured":"Manfredsson F.P.; Lewin A.S.; Mandel R.J.; RNA knockdown as a potential therapeutic strategy in Parkinson\u2019s disease. Gene Ther  2006,13(6),517-524","journal-title":"Gene Ther"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.nano.2018.01.020","volume":"14","author":"Hu K.","year":"2018","unstructured":"Hu K.; Chen X.; Chen W.; Zhang L.; Li J.; Ye J.; Zhang Y.; Zhang L.; Li C.H.; Yin L.; Guan Y.Q.; Neuroprotective effect of gold nanoparticles composites in Parkinson\u2019s disease model. Nanomedicine  2018,14(4),1123-1136","journal-title":"Nanomedicine"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"32901","DOI":"10.1021\/acsami.2c06981","volume":"14","author":"Wang W.","year":"2022","unstructured":"Wang W.; Zheng J.; Zhou H.; Liu Q.; Jia L.; Zhang X.; Ge D.; Shi W.; Sun Y.; Polydopamine-Based Nanocomposite as a Biomimetic Antioxidant with a Variety of Enzymatic Activities for Parkinson\u2019s Disease. ACS Appl Mater Interfaces  2022,14(29),32901-32913","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/15376516.2018.1502386","volume":"28","author":"Khanam S.","year":"2018","unstructured":"Khanam S.; Naz F.; Ali F.; Smita Jyoti R.; Fatima A.; Khan W.; Singh B.R.; Naqvi A.H.; Siddique Y.H.; Effect of cabergoline alginate nanocomposite on the transgenic Drosophila melanogaster model of Parkinson\u2019s disease. Toxicol Mech Methods  2018,28(9),699-708","journal-title":"Toxicol Mech Methods"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1166\/jnn.2016.11103","volume":"16","author":"Umarao P.","year":"2016","unstructured":"Umarao P.; Bose S.; Bhattacharyya S.; Kumar A.; Jain S.; Neuroprotective Potential of Superparamagnetic Iron Oxide Nanoparticles Along with Exposure to Electromagnetic Field in 6-OHDA Rat Model of Parkinson\u2019s Disease. J Nanosci Nanotechnol  2016,16(1),261-269","journal-title":"J Nanosci Nanotechnol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1021\/acsnano.5b08045","volume":"10","author":"Kwon H.J.","year":"2016","unstructured":"Kwon H.J.; Cha M.Y.; Kim D.; Kim D.K.; Soh M.; Shin K.; Hyeon T.; Mook-Jung I.; Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer\u2019s Disease. ACS Nano  2016,10(2),2860-2870","journal-title":"ACS Nano"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"9408","DOI":"10.1002\/anie.201805052","volume":"57","author":"Kwon H.J.","year":"2018","unstructured":"Kwon H.J.; Kim D.; Seo K.; Kim Y.G.; Han S.I.; Kang T.; Soh M.; Hyeon T.; Ceria Nanoparticle Systems for Selective Scavenging of Mitochondrial, Intracellular, and Extracellular Reactive Oxygen Species in Parkinson\u2019s Disease. Angew Chem Int Ed  2018,57(30),9408-9412","journal-title":"Angew Chem Int Ed"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms17060904","volume":"17","author":"Sarkar S.","year":"2016","unstructured":"Sarkar S.; Raymick J.; Imam S.; Neuroprotective and Therapeutic Strategies against Parkinson\u2019s Disease: Recent Perspectives. Int J Mol Sci  2016,17(6),904","journal-title":"Int J Mol Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ejpb.2013.03.034","volume":"85","author":"Herr\u00e1n E.","year":"2013","unstructured":"Herr\u00e1n E.; Ruiz-Ortega J.\u00c1.; Aristieta A.; Igartua M.; Requejo C.; Lafuente J.V.; Ugedo L.; Pedraz J.L.; Hern\u00e1ndez R.M.; In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson\u2019s disease. Eur J Pharm Biopharm  2013,85(3)(3 Pt B),1183-1190","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s12906-017-1922-x","volume":"17","author":"Wang X.S.","year":"2017","unstructured":"Wang X.S.; Zhang Z.R.; Zhang M.M.; Sun M.X.; Wang W.W.; Xie C.L.; Neuroprotective properties of curcumin in toxin-base animal models of Parkinson\u2019s disease: a systematic experiment literatures review. BMC Complement Altern Med  2017,17(1),412","journal-title":"BMC Complement Altern Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2217\/nnm.14.165","volume":"10","author":"da Rocha Lindner G.","year":"2015","unstructured":"da Rocha Lindner G.; Bonfanti Santos D.; Colle D.; Gasnhar Moreira E.L.; Daniel Prediger R.; Farina M.; Khalil N.M.; Mara Mainardes R.; Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism. Nanomedicine (Lond)  2015,10(7),1127-1138","journal-title":"Nanomedicine (Lond)"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnagi.2015.00020","volume":"7","author":"Esteves M.","year":"2015","unstructured":"Esteves M.; Crist\u00f3v\u00e3o A.C.; Saraiva T.; Rocha S.M.; Baltazar G.; Ferreira L.; Bernardino L.; Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson\u2019s disease. Front Aging Neurosci  2015,7,20","journal-title":"Front Aging Neurosci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"10396","DOI":"10.1038\/s41598-017-11220-1","volume":"7","author":"Johnsen K.B.","year":"2017","unstructured":"Johnsen K.B.; Burkhart A.; Melander F.; Kempen P.J.; Vejlebo J.B.; Siupka P.; Nielsen M.S.; Andresen T.L.; Moos T.; Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci Rep  2017,7(1),10396","journal-title":"Sci Rep"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"011905","DOI":"10.1063\/5.0130259","volume":"35","author":"Abazari M.A.","year":"2023","unstructured":"Abazari M.A.; Soltani M.; Kashkooli F.M.; Targeted nano-sized drug delivery to heterogeneous solid tumor microvasculatures: Implications for immunoliposomes exhibiting bystander killing effect. Phys Fluids  2023,35(1),011905","journal-title":"Phys Fluids"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"112117","DOI":"10.1016\/j.biopha.2021.112117","volume":"143","author":"Nguyen T.T.","year":"2021","unstructured":"Nguyen T.T.; Dung Nguyen T.T.; Vo T.K.; Tran N.M.; Nguyen M.K.; Van Vo T.; Nanotechnology-based drug delivery for central nervous system disorders. Biomed pharmacoth  2021,143,112117","journal-title":"Biomed pharmacoth"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"72594","DOI":"10.3389\/fbioe.2021.672594","volume":"96","author":"Li A.","year":"2021","unstructured":"Li A.; Tyson J.; Patel S.; Patel M.; Katakam S.; Mao X.; He W.; Emerging Nanotechnology for Treatment of Alzheimer\u2019s and Parkinson\u2019s Disease. Front Bioeng Biotechnol  2021,96,72594","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"288121690","DOI":"10.1016\/j.biomaterials.2022.121690","author":"Zhong G.","year":"2022","unstructured":"Zhong G.; Long H.; Zhou T.; Liu Y.; Zhao J.; Han J.; Yang X.; Yu Y.; Chen F.; Shi S.; Blood-brain barrier Permeable nanoparticles for Alzheimer\u2019s disease treatment by selective mitophagy of microglia. Biomaterials  2022,288121690","journal-title":"Biomaterials"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"105314","DOI":"10.1016\/j.ejps.2020.105314","volume":"148","author":"Pinheiro R.G.R.","year":"2020","unstructured":"Pinheiro R.G.R.; Granja A.; Loureiro J.A.; Pereira M.C.; Pinheiro M.; Neves A.R.; Reis S.; Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer\u2019s disease. Eur J Pharm Sci  2020,148,105314","journal-title":"Eur J Pharm Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11095-020-02865-1","volume":"37","author":"Pinheiro R.G.R.","year":"2020","unstructured":"Pinheiro R.G.R.; Granja A.; Loureiro J.A.; Pereira M.C.; Pinheiro M.; Neves A.R.; Reis S.; RVG29-Functionalized Lipid Nanoparticles for Quercetin Brain Delivery and Alzheimer\u2019s Disease. Pharm Res  2020,37(7),139","journal-title":"Pharm Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"107968","DOI":"10.1016\/j.dyepig.2019.107968","volume":"173","author":"Cai J.","year":"2020","unstructured":"Cai J.; Dao P.; Chen H.; Yan L.; Li Y.L.; Zhang W.; Li L.; Du Z.; Dong C-Z.; Meunier B.; Ultrasmall superparamagnetic iron oxide nanoparticles-bound NIR dyes: Novel theranostic agents for Alzheimer\u2019s disease. Dyes Pigments  2020,173,107968","journal-title":"Dyes Pigments"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"44180","DOI":"10.1021\/acsami.0c13223","volume":"12","author":"Sharma M.","year":"2020","unstructured":"Sharma M.; Tiwari V.; Shukla S.; Panda J.J.; Fluorescent Dopamine\u2013Tryptophan Nanocomposites as Dual-Imaging and Antiaggregation Agents: New Generation of Amyloid Theranostics with Trimeric Effects. ACS Appl Mater Interfaces  2020,12(39),44180-44194","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/chem.201404562","volume":"21","author":"Gao N.","year":"2015","unstructured":"Gao N.; Sun H.; Dong K.; Ren J.; Qu X.; Gold-nanoparticle-based multifunctional amyloid-\u03b2 inhibitor against Alzheimer\u2019s disease. Chemistry  2015,21(2),829-835","journal-title":"Chemistry"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2002804","DOI":"10.1002\/smll.202002804","volume":"16","author":"Gao W.","year":"2020","unstructured":"Gao W.; Wang W.; Dong X.; Sun Y.; Nitrogen\u2010Doped Carbonized Polymer Dots: A Potent Scavenger and Detector Targeting Alzheimer\u2019s \u03b2. Amyloid Plaques Small  2020,16(43),2002804","journal-title":"Amyloid Plaques Small"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s11095-017-2240-1","volume":"34","author":"Mittapelly N.","year":"2017","unstructured":"Mittapelly N.; Thalla M.; Pandey G.; Banala V.T.; Sharma S.; Arya A.; Mishra S.; Mitra K.; Shukla S.; Mishra P.R.; Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer\u2019s Disease: a Proof of Concept Study. Pharm Res  2017,34(11),2322-2335","journal-title":"Pharm Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1567201815666181004094707","volume":"16","author":"Sunena","year":"2018","unstructured":"Sunena ; Singh S.K.; Mishra D.N.; Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice. Curr Drug Deliv  2018,16(1),51-58","journal-title":"Curr Drug Deliv"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2217\/rme-2016-0032","volume":"11","author":"Misra S.","year":"2016","unstructured":"Misra S.; Chopra K.; Saikia U.N.; Sinha V.R.; Sehgal R.; Modi M.; Medhi B.; Effect of mesenchymal stem cells and galantamine nanoparticles in rat model of Alzheimer\u2019s disease. Regen Med  2016,11(7),629-646","journal-title":"Regen Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.3109\/10717544.2016.1153748","volume":"23","author":"Hanafy A.S.","year":"2016","unstructured":"Hanafy A.S.; Farid R.M.; Helmy M.W.; ElGamal S.S.; Pharmacological, toxicological and neuronal localization assessment of galantamine\/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer\u2019s disease management. Drug Deliv  2016,23(8),3111-3122","journal-title":"Drug Deliv"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.013","volume":"150","author":"Mittal G.","year":"2011","unstructured":"Mittal G.; Carswell H.; Brett R.; Currie S.; Kumar M.N.; Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer\u2019s pathology. J Cont Rel  2011,150(2),220-228","journal-title":"J Cont Rel"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40659-016-0093-4","volume":"49","author":"Cao X.","year":"2016","unstructured":"Cao X.; Hou D.; Wang L.; Li S.; Sun S.; Ping Q.; Xu Y.; Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats. Biol Res  2016,49(1),32","journal-title":"Biol Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/10837450.2020.1740257","volume":"25","author":"Arisoy S.","year":"2020","unstructured":"Arisoy S.; Sayiner O.; Comoglu T.; Onal D.; Atalay O.; Pehlivanoglu B.; In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery. Pharm Dev Technol  2020,25(6),735-747","journal-title":"Pharm Dev Technol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.actbio.2020.03.021","volume":"109","author":"Vong L.B.","year":"2020","unstructured":"Vong L.B.; Sato Y.; Chonpathompikunlert P.; Tanasawet S.; Hutamekalin P.; Nagasaki Y.; Self-assembled polydopamine nanoparticles improve treatment in Parkinson\u2019s disease model mice and suppress dopamine-induced dyskinesia. Acta Biomater  2020,109,220-228","journal-title":"Acta Biomater"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/IJN.S151475","volume":"13","author":"Yan X.","year":"2018","unstructured":"Yan X.; Xu L.; Bi C.; Duan D.; Chu L.; Yu X.; Wu Z.; Wang A.; Sun K.; Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS\/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects. Int J Nanomedicine  2018,13,273-281","journal-title":"Int J Nanomedicine"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"119148","DOI":"10.1016\/j.ijpharm.2020.119148","volume":"579","author":"Bhattamisra S.K.","year":"2020","unstructured":"Bhattamisra S.K.; Shak A.T.; Xi L.W.; Safian N.H.; Choudhury H.; Lim W.M.; Shahzad N.; Alhakamy N.A.; Anwer M.K.; Radhakrishnan A.K.; Md S.; Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson\u2019s disease. Int J Pharm  2020,579,119148","journal-title":"Int J Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.nano.2018.08.004","volume":"14","author":"Sridhar V.","year":"2018","unstructured":"Sridhar V.; Gaud R.; Bajaj A.; Wairkar S.; Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson\u2019s disease. Nanomedicine  2018,14(8),2609-2618","journal-title":"Nanomedicine"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.2174\/1381612822666160928145346","volume":"23","author":"Negro S.","year":"2017","unstructured":"Negro S.; Boeva L.; Slowing K.; Fernandez-Carballido A.; Garcia-Garc\u00eda L.; Barcia E.; Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism. Curr Pharm Des  2017,23(23),3423-3431","journal-title":"Curr Pharm Des"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijbiomac.2017.12.056","volume":"109","author":"Raj R.","year":"2018","unstructured":"Raj R.; Wairkar S.; Sridhar V.; Gaud R.; Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol  2018,109,27-35","journal-title":"Int J Biol Macromol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ejps.2012.12.007","volume":"48","author":"Md S.","year":"2013","unstructured":"Md S.; Khan R.A.; Mustafa G.; Chuttani K.; Baboota S.; Sahni J.K.; Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Euro J Pharma Sci  2013,48(3),393-405","journal-title":"Euro J Pharma Sci"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3109\/03639045.2013.789051","volume":"40","author":"Sharma S.","year":"2014","unstructured":"Sharma S.; Lohan S.; Murthy R.S.R.; Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm  2014,40(7),869-878","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5607\/en.2014.23.3.246","volume":"23","author":"Gambaryan P.Y.","year":"2014","unstructured":"Gambaryan P.Y.; Kondrasheva I.G.; Severin E.S.; Guseva A.A.; Kamensky A.A.; Increasing the Effciency of Parkinson\u2019s Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System. Exp Neurobiol  2014,23(3),246-252","journal-title":"Exp Neurobiol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.drudis.2015.02.009","volume":"20","author":"Leyva-G\u00f3mez G.","year":"2015","unstructured":"Leyva-G\u00f3mez G.; Cort\u00e9s H.; Maga\u00f1a J.J.; Leyva-Garc\u00eda N.; Quintanar-Guerrero D.; Flor\u00e1n B.; Nanoparticle technology for treatment of Parkinson\u2019s disease: the role of surface phenomena in reaching the brain. Drug Discov Today  2015,20(7),824-837","journal-title":"Drug Discov Today"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ejpb.2011.10.015","volume":"80","author":"Esposito E.","year":"2012","unstructured":"Esposito E.; Mariani P.; Ravani L.; Contado C.; Volta M.; Bido S.; Drechsler M.; Mazzoni S.; Menegatti E.; Morari M.; Cortesi R.; Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study. Eur J Pharm Biopharm  2012,80(2),306-314","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jps.22285","volume":"100","author":"Tsai M.J.","year":"2011","unstructured":"Tsai M.J.; Huang Y.B.; Wu P.C.; Fu Y.S.; Kao Y.R.; Fang J.Y.; Tsai Y.H.; Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci  2011,100(2),547-557","journal-title":"J Pharm Sci"},{"key":"ref=105","first-page":"1599","volume":"7","author":"Wen C.J.","year":"2012","unstructured":"Wen C.J.; Zhang L.W.; Al-Suwayeh S.A.; Yen T.C.; Fang J.Y.; Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomedicine  2012,7,1599-1611","journal-title":"Int J Nanomedicine"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"405101","DOI":"10.1088\/0957-4484\/21\/40\/405101","volume":"21","author":"Hsu S.H.","year":"2010","unstructured":"Hsu S.H.; Wen C.J.; Al-Suwayeh S.A.; Chang H.W.; Yen T.C.; Fang J.Y.; Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug. Nanotechnology  2010,21(40),405101","journal-title":"Nanotechnology"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/jgm.1361","volume":"11","author":"Huang R.","year":"2009","unstructured":"Huang R.; Han L.; Li J.; Ren F.; Ke W.; Jiang C.; Pei Y.; Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med  2009,11(9),754-763","journal-title":"J Gene Med"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.nano.2012.02.009","volume":"8","author":"Martinez-Fong D.","year":"2012","unstructured":"Martinez-Fong D.; Bannon M.J.; Trudeau L.E.; Gonzalez-Barrios J.A.; Arango-Rodriguez M.L.; Hernandez-Chan N.G.; Reyes-Corona D.; Armend\u00e1riz-Borunda J.; Navarro-Quiroga I.; NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson\u2019s disease. Nanomedicine  2012,8(7),1052-1069","journal-title":"Nanomedicine"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201820666230707113405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/218515\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201820666230707113405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T17:10:04Z","timestamp":1713978604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/218515\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":108,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201820666230707113405","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}